Safety of the Herpes Zoster Subunit Vaccine in Lupus

Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures

2. Female or male ≥18 years of age at the time of signing the informed consent

3. Meet the 2019 EULAR/ACR Classification Criteria for SLE

4. Female subjects must use 1 effective method of avoiding pregnancy, from the timethey sign consent until end of the study period unless the subject is surgicallysterile (e.g., bilateral oophorectomy or complete hysterectomy), has a sterile malepartner, is at least 1 year postmenopausal, or practices sustained abstinenceconsistent with the subject's customary lifestyle. Postmenopausal is defined as atleast 1 year since last menses and the subject has an elevated follicle-stimulatinghormone (FSH) level greater than the threshold laboratory value of post-menopausalwomen at screening.

Exclusion Criteria:

1. Prior administration of the Herpes Zoster subunit vaccine (Shingrix) or theVaricella-Zoster virus vaccine live (Zostavax)

2. Clinical HZ infection within 12 months prior to screening or during screening

3. Hybrid SLEDAI >12 at screening visit

4. Presence of a mild, moderate, or severe flare per the rSFI at time of screenin

5. Increase in clinical SLEDAI parameters at time of enrollment relative to screeningvisit

6. Any vaccine, including the final/booster dose of any SARS-CoV-2 vaccine, within sixweeks enrollment

7. Receipt of rituximab or cyclophosphamide within nine months of enrollment

8. Participation in an interventional clinical trial of SLE or other therapeuticswithin six months of enrollment

9. Moderate to severe infectious febrile illness or use of systemic antibiotics (antibacterial, antiviral, antifungal, or antiparasitic agent) within 4 weeks ofenrollment

10. Are pregnant, nursing, or planning a pregnancy while enrolled in the study

11. Known primary or secondary immunodeficiency (malignancy, HIV, common variable immunedeficiency) or medications used during cancer chemotherapy